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Over the last 20 years, adjuvant chemotherapy has been administered after surgical resection of tumors for colorec-
tal cancer (CRC) patients with stage III disease to reduce the risk of recurrence of cancer. However, it is controversial 
as to whether all stage II CRC patients, or at least stage II CRC patients with additional risk factors, should receive 
adjuvant chemotherapy. Adjuvant chemotherapy in stage II CRC patients may be considered for patients in high-risk 
groups. It is a high priority to define prognostic factors for these stage II CRC patients to identify high-risk patients at 
risk of tumor metastases or recurrence and referral of stage II CRC patients for individual assessment. Recent guide-
lines advocate the consideration of clinicopathological factors such as free bowel perforation or obstruction, lym-
phatic and vascular invasion, poorly differentiated tumors, fewer than 12 lymph nodes examined, tumors with adjacent 
organ involvement, and indeterminate or positive margins as strong predictors of a poor prognosis in stage II CRC. 
Furthermore, with recent advances in basic research attempting to elucidate the underlying molecular mechanisms of 
carcinogenesis, a variety of candidate genes with potential value for the early detection of cancer have been discovered. 
Molecular factors such as microsatellite stability and loss of heterozygosity of 18q have been used to identify groups 
of patients with stage II CRC who have much worse prognoses and may benefit from administration of chemotherapy. 
Accumulated reports have described the detection of circulating tumor cell-related molecular markers in the periph-
eral blood of CRC patients, which has important prognostic and therapeutic implications. Consequently, therapeutic 
decision-making models are likely to be further refined by the inclusion of such molecular markers.
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Introduction
Colorectal cancer (CRC) is a significant problem 
worldwide, and while it accounts for 10% of all 
cancers, it is the third leading cause of cancer deaths 
in the Western world.1 CRC is one of the most com-
mon malignancies in Taiwan, and is also the third 
major cause of cancer deaths in Taiwan. More than 
10,000 new cases were diagnosed, and over 4100 
patients died from this disease in 2007. Consequently, 
the incidence of CRC has gradually approached 
Western levels in recent decades. The most impor-
tant prognostic indicator for survival in CRC is the 
tumor stage. Currently, TNM classification from the 
American Joint Committee on Cancer/International 
Union Against Cancer (AJCC/UICC) staging systems 
for CRC, which is determined by depth penetration 
through the bowel wall, the number of lymph 
nodes, and the presence of distant metastasis in-
volved, provides more detailed information than 
other staging systems.2
Adjuvant chemotherapy with 5-fluorouracil (5-
FU)/leucovorin modulated by folinic acid com-
bined with oxaliplatin significantly improves 5-year 
disease-free survival and 6-year overall survival in 
stage III colon cancer patients, and it should be 
considered after surgery for patients with stage III 
disease.3 However, the use of adjuvant chemo-
therapy for stage II patients remains controversial. 
Patients with stage II colon cancer constitute a 
particularly heterogenous population. Routine chem-
otherapy administration may be inappropriate and 
costly for all stage II patients;4 therefore, it is not 
recommended that patients with stage II CRC un-
dergo routine adjuvant chemotherapy, compared 
with patients with positive lymph nodes (AJCC 
stage III).5
However, approximately 25−30% of CRC patients 
with stage II disease are at high risk for postopera-
tive relapse. Indeed, the clinical outcome of patients 
with high-risk stage II disease is similar to that of 
patients with stage III disease.6 Therefore, it is 
important to identify high-risk stage II CRC pa-
tients for whom adjuvant chemotherapy may yield 
potential benefits.
In recent guidelines, factors such as free bowel 
perforation or occlusion, lymphatic and vascular 
invasion, depth of tumor invasion and adjacent organ 
involvement, detection of occult neoplastic cells 
in lymph nodes, and extramural venous invasion 
and peritoneal involvement have been considered 
when assessing the likely benefit-risk ratio. More 
importantly, molecular markers such as loss of het-
erozygosity of 18q or presence of microsatellite 
instability (MSI), allelic imbalance, and levels of 
thymidylate synthase have facilitated the identifi-
cation of subgroups of patients with stage II CRC 
who should (or should not) be treated.7 Therefore, 
molecular biomarkers might be valuable for 
identification of high-risk stage II CRC patients.
It is well known that tumor cell dissemination 
and formation of metastases are the result of mul-
tiple steps involving patient- and tumor-related 
factors. Possible mechanisms for the persistence 
of disseminated tumor cells in the circulating ve-
nous or lymphatic streams may be an immune es-
cape mechanism or a higher malignant potential of 
this specific clone. Disseminated tumor cells in blood 
and bone marrow have been shown to be valid 
markers in patients with CRC.8 However, none of 
these markers are currently used in clinical practice 
for making decisions on whether a patient with 
stage II CRC should receive adjuvant chemotherapy. 
Recently, detection of circulating tumor cells in 
blood samples of patients with stage II CRC has 
identified patients with poor outcomes.8 However, 
this finding needs to be confirmed by further large 
studies to evaluate whether these factors are ap-
propriate as prognostic markers in patients with 
stage II CRC.
This article reviews updated information regard-
ing prognostic and molecular aspects of stage II CRC 
patients who have undergone curative resection, 
and it also evaluates the significance of such aspects 
in postoperative surveillance, and the impact on 
therapeutic strategies. 
Conventional Prognostic Factors in 
Stage II Colorectal Cancer
New American Joint Committee on the 
cancer staging system
Compatible with other staging systems, the TNM 
classification for carcinoma of the colon and rec-
tum provides more detail about both clinical and 
pathologic staging. The 5-year survival rate for pa-
tients with CRC is largely dependent on the TNM 
stage. TNM staging is based on the depth of tumor 
invasion into or beyond the wall of the colorectum 
(T), invasion of or adherence to adjacent organs or 
structures (T), the number of regional lymph nodes 
involved (N), and the presence or absence of distal 
metastasis (M).2
In the sixth edition of the AJCC/UICC staging 
systems published in 2002, stage II CRC was subdi-
vided into IIA and IIB. The seventh edition is based 
on survival and relapse data that were not available 
for the prior edition, and further substaging of 
stage II was accomplished, and this is subdivided 
into IIA (T3N0), IIB (T4aN0) and IIC (T4bN0). T4 lesions 
are subdivided into T4a (tumor penetrating the 
surface of the visceral peritoneum) and T4b (tumor 
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directly invading or is histologically adherent to 
other organs or structures).2 The importance of 
adjacent organs and parietal peritoneum involve-
ment is the key factor for the amendment of stage II 
CRC by AJCC/UICC staging systems.
Assessment of the number and extent of 
lymph node involvement
Tumor penetration depth and lymph node metas-
tases have been regarded as significant prognostic 
determinants for patients with CRC. The number 
of lymph nodes sampled should be recorded in the 
assessment of pN. The number of nodes examined 
from a surgical specimen that is located along the 
mesocolic border of the colon has been reported 
to be associated with improved survival.2,9,10 The 
presence or absence of lymph node metastasis or 
the extent of lymph node involvement is one of the 
most important determinants of prognosis in patients 
with CRC. Therefore, the presence of nodal metas-
tases provides important prognostic information 
for therapeutic strategies.9
Over the past 60 years, numerous studies have 
demonstrated that long-term survival following 
CRC resection is inversely related to the degree of 
penetration of the primary tumor through the bowel 
wall and the presence of metastasis in adjacent 
lymph nodes.6 The current guidelines from AJCC/
UICC recommend that it is important to obtain 
at least 10−14 lymph nodes in radical colon and rec-
tum resections for accurate staging.2 Furthermore, 
several recent studies have suggested that the 
minimal number of nodes examined should be be-
tween 8 and 20.9−11 There is a consistent risk of a 
stage III patient being mistakenly classified as 
stage II when no sufficient lymph nodes are re-
trieved and then being denied adjuvant chemo-
therapy. Therefore, an accurate assessment of the 
tumor lymph nodes in the resected specimen is es-
sential for reducing the risk of under-staging. The 
5-year survival rate exceeds 75% in patients with 
tumors confined to the bowel wall without lymph 
node involvement, whereas in those with exten-
sive lymph node involvement, it is approximately 
30−60%.9,11,12
Our recent study9 has suggested that an increase 
in the number of tumor-free lymph nodes is clini-
cally important, and this parameter should be taken 
into consideration in CRC patients without meta-
static lymph nodes. Despite the extent of lymph 
node dissection or the numbers of lymph nodes 
harvested not greatly improving accurate tumor 
staging, the increased examined numbers of tumor-
free lymph nodes might decrease the incidence of 
under-staging and provide further therapies for 
these patients.
Lymphatic, vascular and 
perineural invasion
Lymphatic and vascular invasion represent crucial 
steps in the formation of micrometastases and 
metastases, but some studies have shown venous 
invasion to be more important than lymphatic inva-
sion, whereas other studies have shown the opposite. 
Some of the variation in the reported studies prob-
ably relates to interobserver variability among patho-
logists.13 Vascular invasion by primary tumors may 
indicate that cancer cells have spread throughout 
the body, and they have been used as a prognostic 
factor for predicting recurrence or metastases.14,15 
However, Khankhanian et al16 suggested that vascular 
invasion within the bowel wall is not an important 
prognostic factor among patients with stage II 
CRC. There are no widely accepted standards for 
patho logical evaluation of vascular invasion. Lymph o-
vascular invasion is considered high risk and an indi-
cation for administering chemotherapy, warranted by 
the National Comprehensive Cancer Network Clinical 
Practice Guidelines in Oncology Version 1, 2010.
Fujita et al17 reported that perineural invasion 
status can be used to facilitate the selection of CRC 
patients for adjuvant chemotherapy and that it 
should be described in routine pathologic reports. 
Similarly, the results of our previous study revealed 
that the presence of perineural invasion might lead 
to postoperative early relapse in either colonic or 
rectal cancer. In addition, vascular invasion is not a 
significant factor in predicting postoperative early 
relapse of rectal cancer, but it is significant in colon 
cancer. Perhaps this is due to the more complicated 
vascular supply in the colon than in the rectum.18
Stage II colorectal cancer and 
indications for treatment
The overall survival in stage II CRC patients is ap-
proximately 70−80% at a 5-year interval after radical 
resection, and in high risk stage II CRC, the clinical 
outcome is similar to that of patients with stage III 
disease. Recognition of heterogeneity has led to an 
increasing focus on the factors that influence prog-
nosis, and also to an intensive search for reliable 
prognostic markers and markers predictive of a 
likely response to adjuvant therapy.11
Clinical guidelines for management of stage II 
CRC state that the standard of care is surgical re-
section alone. However, these guidelines are based 
on the statement that adjuvant chemotherapy may 
be considered in cases where there are pathological 
features of poor prognosis. A wide variety of poten-
tial clinical and pathological risk factors for stage II 
CRC recurrence or metastases have been investi-
gated. The most important pathological risk factors 
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for predicting the risk of recurrence or metastases 
are (1) emergency presentation (free bowel perfo-
ration or occlusion); (2) detection of lymphatic and 
vascular invasion in the primary tumors; (3) depth 
of tumor invasion and adjacent organ involvement; 
and (4) detection of occult neoplastic cells in lymph 
nodes, extramural venous invasion, and peritoneal 
involvement. Other possible factors are much more 
controversial, such as tumor location (left vs. right, 
distal or proximal to splenic flexure), age, differen-
tiation and sex.6,11,19
The widespread use of 5-FU/leucovorin or 5-FU/
leucovorin plus oxaliplatin adjuvant chemotherapy 
regimens for the treatment of patients with stage III 
CRC has led to a significant improvement in the 
prognosis of these patients. The key issue in devel-
oping treatment strategy is the heterogenous na-
ture of stage II disease, which results in a wide range 
of postresection prognosis.11 In contrast to CRC pa-
tients with positive lymph nodes (stage III) where 
adjuvant chemotherapy is beneficial, the use of 
adjuvant chemotherapy for patients with stage II 
remains controversial. The International Multicenter 
Pooled Analysis of Colon Cancer Trials B2 study,20 
which combined data from patients in five separate 
trials, showed that stage II CRC patients are gener-
ally considered to be at low risk for developing post-
operative relapse and do not show any statistically 
significant benefit of 5-FU/leucovorin combination 
over surgery alone. Recently, an American Society 
of Clinical Oncology panel21 reviewed the available 
literature-based evidence regarding adjuvant therapy 
in stage II patients. The data revealed that although 
there was evidence of improvement in disease-free 
survival with adjuvant therapy, the direct evidence 
from randomized controlled trials did not support the 
routine use of adjuvant chemotherapy for patients 
with stage II CRC because of insignificant improve-
ment in overall survival.21 Although available evi-
dence does not support the routine use of adjuvant 
chemotherapy in all patients with stage II CRC, ther-
apy should be considered for poor prognosis patients 
who possess such risk factors, as previously described.
In contrast, the National Surgical Adjuvant Breast 
and Bowel Project showed that the relative bene-
fits were largely the same for patients with stage II 
and stage III tumors for both disease-free survival 
and overall survival.22 These data were supported by 
a meta-analysis from the Mayo Clinic that was de-
rived from 3341 patients with both node-negative 
and node-positive colon cancer.23 A report from the 
Quick and Simple and Reliable (QUASAR) study com-
pared adjuvant 5-FU-based therapy with observation 
in 3238 CRC patients (91% Dukes’ B) from 150 centers 
in 17 countries. The results of the QUASAR study 
are an important advancement in understanding 
the value of adjuvant 5-FU-based chemotherapy, 
at least for some stage II patients.24 Therefore, over-
all, these studies suggest that chemotherapy can 
lead to a similar incremental benefit of survival for 
stage II patients (node-negative CRC), as demon-
strated for stage III patients (node-positive CRC).
The Multicenter International Study of Oxaliplatin 
5-FU/leucovorin in the Adjuvant Treatment of 
Colon Cancer trial, which randomized patients to 
receive either infusional 5-FU or infusional 5-FU 
with oxaliplatin (FOLFOX4), showed a significant 
improvement in 3-year disease-free survival for 
more than 1100 patients (node-negative vs. node-
positive: 40% vs. 60%) who were treated with 
FOLFOX.25 Growing evidence that the prognosis of 
certain stage II CRC patients with unfavorable 
prognostic factors can be improved by adjuvant 
chemotherapy indicates the need to identify novel 
predictive factors to guide the identification of 
stage II CRC patients who are likely to experience 
metastases and recurrence. Consequently, to im-
prove the clinical outcome of patients with stage II 
CRC, further studies are required to identify novel 
panels of molecular and biochemical markers that 
may be used to predict benefit of adjuvant treat-
ment in stage II CRC.
Molecular (Biological) Markers
Two distinct mutational pathways have been iden-
tified that result in CRC. The tumor suppressor 
pathway, also termed the chromosomal instability 
pathway, accounts for approximately 85% of all 
colorectal carcinomas and most sporadic colorectal 
carcinomas. These genetic changes result in the 
mutational activation of oncogenes coupled with 
mutational inactivation of tumor suppressor genes.26 
The second mutational pathway, characterized by 
the inactivation of both alleles of one of the DNA 
mismatch repair genes, accounts for approximately 
15% of all CRCs. The DNA mismatch repair gene 
results in variations in the length, and therefore, 
instability of short tandem DNA sequences known as 
microsatellites. A number of markers determined 
from several retrospective studies can now define 
patients with a high risk factor for metastases or 
recurrence of both stage II and III disease.27 We have 
critically reviewed the data examining potential 
molecular markers of prognosis and response to 
therapy for patients with stage II CRC as follows.
Microsatellite instability
Defects in mismatch repair lead to high-frequency 
MSI in CRC. One of the most extensively investigated 
molecular markers is MSI, which occurs in approxi-
mately 15% of CRCs. High-frequency MSI tends to 
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be associated with distinct clinical and pathological 
tumor characteristics, e.g. located proximal to the 
splenic flexure, mucinous cell type, peritumoral 
lymphocytic infiltration, poor differentiation, and 
diploidy.10 MSI has been investigated in a number of 
studies as an independent marker of prognosis and 
response to therapy, and it was found to be a predic-
tor of favorable outcomes compared with microsat-
ellite stability tumors at each stage, with the 5-year 
survival rate being significantly better in those pa-
tients whose tumors exhibited high-frequency MSI.28
Fluorouracil-based adjuvant chemotherapy ben-
efits patients with stage II or III colon cancer with 
microsatellite-stable tumors or tumors exhibiting 
low-frequency MSI, but not those with tumors ex-
hibiting high-frequency MSI.28 Halling et al29 studied 
508 patients with resected stage II and III CRC and 
found that high-frequency MSI was an independent 
predictor of improved survival and time to recur-
rence. Parc et al30 observed a significantly better 
disease-free survival rate in patients whose tumors 
presented as MSI, and they also observed a trend for 
the probability of a longer overall survival period. 
Adjuvant chemotherapy may be inappropriate and 
of little or no benefit for stage II CRC patients pre-
senting with high-frequency MSI, because the prog-
nosis for these patients is already good. In contrast, 
the National Surgical Adjuvant Breast and Bowel 
Project did not find that MSI was a predictive marker 
for response to 5-FU; patients with MSI and micro-
satellite stability were found to benefit equally 
from the use of adjuvant chemotherapy.31 Currently, 
the role of these predictive markers is being tested 
in stage II patients in a Gastrointestinal Intergroup 
study conducted by the Eastern Cooperative 
Oncology Group (E5202), which is addressing their 
potential as predictors of chemotherapy response.
Overexpression or lack of expression of 
the “deleted in colorectal cancer” gene
Another leading candidate marker is the allelic 
loss of chromosome 18q, which is associated with 
tumor progression and is related to the “deleted in 
colorectal cancer” gene. The loss of one allele is 
referred to as a loss of heterozygosity. The most 
promising candidate markers at present are MSI 
and allelic loss of chromosome 18q. Halling et al29 
did not find that allelic deletion of 18q was prognos-
tic in stage II and III CRC. However, several studies 
have demonstrated that patients with retention of 
both 18q alleles have a more favorable outcome 
after adjuvant 5-FU-based chemotherapy in stage II 
disease.32−34 Lanza et al33 observed that stage II can-
cer patients with intact 18q alleles have an excel-
lent clinical outcome with a 5-year disease free 
survival of 96%. Similarly, Zhou et al34 found that the 
5-year disease free survival of patients with stage II 
CRC was 100% for those with no allelic balance com-
pared with 58% for those with allelic imbalances of 
chromosomes 8p and 18q. Collectively, these data 
support the role of 18q loss of heterozygosity as a 
prognostic indicator in curable disease, and this 
may identify patients who will benefit from adju-
vant chemotherapy in stage II CRC.
Thymidylate synthase and 
dihydropyrimidine dehydrogenase
Thymidylate synthase is a key enzyme in DNA syn-
thesis, and a number of enzymes affect the efficacy 
of 5-FU. The enzyme dihydropyrimidine dehydro-
genase metabolizes and inactivates 5-FU in the 
liver. Kornmann et al35 investigated the association 
of thymidylate synthase and dihydropyrimidine de-
hydrogenase mRNA levels with recurrence-free 
survival in patients with stage II and III CRC who were 
receiving adjuvant 5-FU-based chemotherapy. 
They found that high levels of thymidylate synthase 
and dihydropyrimidine dehydrogenase were asso-
ciated with resistance to 5-FU in advanced color-
ectal cancer. Thymidylate synthase mRNA levels may 
be a useful marker to predict the time to recur-
rence in patients with colorectal cancer who are 
receiving adjuvant 5-FU treatment.35 However, 
these findings need to be further evaluated in large 
prospective studies that may identify patients un-
likely to benefit from 5-FU but who may benefit from 
an alternative chemotherapeutic drug. Additional 
studies with consistent methodology are required 
to define the precise prognostic value of thymidylate 
synthase and dihydropyrimidine dehydrogenase.
Circulating tumor cells and 
micrometastases
During metastasis, the cells escape the host’s defense 
mechanism, finally forming a new metastatic lesion 
with tumor cells spreading through the blood stream 
and lymphatic system. The importance of circulat-
ing tumor cell emboli in the spread of metastases 
has been reported.36,37 Because dissemination of 
neoplastic cells is the main determinant of distant 
metastases or recurrence and cancer-related death, 
detection of micrometastases and circulating tumor 
cells in patients undergoing surgery for cure of 
malignancy remains a challenge for oncologists. 
Undetected micrometastases can contribute to the 
failure of primary treatment. Therefore, the iden-
tification of occult metastases in patients with early 
stage cancer could have a substantial clinical impact 
on the optimal therapy and prognosis for patients 
with CRC. However, such neoplastic cells may be 
present in the bloodstream in very low numbers 
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and may not be detected by conventional methods. 
Among the current possibilities, one of the most 
compelling diagnostic methods is the development 
of a highly sensitive molecular diagnostic proce-
dure for tissues and biological fluids, especially 
peripheral blood.36,37
Some studies have shown that micrometastases 
do occur and molecular detection of micrometas-
tases is a prognostic tool in stage II CRC.8,36,38 Koch 
et al8 showed the prognostic significance of 
tumor cells detected in blood samples of patients 
with stage II CRC using cytokeratin-20 reverse 
transcription-polymerase chain reaction. Likewise, 
Lloyd et al38 showed that detection of marker-
positive cells by immunobead reverse transcription-
polymerase chain reaction in peritoneal lavage fluid 
taken during laparotomy was a significant risk fac-
tor for reduced survival after curative resection. 
Consistent with these studies, positive circulating 
tumor cells are a potential auxiliary tool for conven-
tional clinic opathological variables for the prediction 
of postoperative relapse in stage II CRC patients who 
have undergone curative resection.36 Conversely, 
some studies have shown that antibodies against cy-
tokeratins and carcinoembryonic antigen have been 
used to detect micrometastases but they disagree 
about the prognostic significance of such a finding. 
Simul taneously, several recent studies have reported 
conflicting results regarding the prognostic value of 
CTCs.39,40 Differences in the choice of antibody, 
technique of staining procedures and interpretation 
may explain in part these differing results.41
Consequently, further studies are required to 
determine whether the introduction of adjuvant 
chemotherapy for stage II CRC patients with positive 
CTCs is appropriate.36 Monitoring of circulating 
tumor cells in stage II CRC patients might be ad-
vantageous in postoperative surveillance and might 
also be useful for evaluation of further adjuvant 
therapeutic strategies after surgery. However, large 
scale and long-term clinical follow-ups are war-
ranted to address the clinical significance of stage II 
CRC for adjuvant chemotherapy.
Conclusion
Optimal tailored chemotherapy aims to treat stage II 
CRC patients under effective and safe guidelines. 
The relevant data are contradictory in several as-
pects, although a prognostic significance is suggested 
for many of the molecular biological alterations 
that are causally associated with the genesis of CRC. 
Up-to-date, randomized controlled trials and meta-
analyses have uniformly failed to definitively detect 
a survival benefit for adjuvant chemotherapy in 
stage II CRC. Nonetheless, there remains no biological 
or clinical reason that the clinical behavior of 
stage II tumors should be different from that of 
stage III tumors. Combining conventional prognostic 
markers and molecular markers as predictive fac-
tors may warrant clarifying the guidelines for man-
agement of this disease in relation to recom mendation 
for further adjuvant chemotherapy.
In the near future, more well-designed and larger 
clinical trials may be needed to support the prog-
nostic significance of circulating tumor cells with 
stage II CRC. In addition, it will be necessary to 
analyze clinical data from multiple institutions to 
develop more sensitive, simpler, and specific cri-
teria and biomarkers for detecting patients with a 
probable high risk of post-operative relapse.
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